Liposomal formulations of anthracycline agents and cytidine analogs
AssigneeCelator Pharmaceuticals, Inc.
InventorsLawrence Mayer, Sharon Johnstone, Troy Harasym
Life of this patent
Estimating the term…
Abstract
Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.
Claims10
A composition for parental administration to a subject which composition comprises liposomes having associated therewith daunorubicin and cytarabine, and wherein
- (a) the daunorubicin and cytarabine are co-encapsulated;
- (b) the daunorubicin:cytarabine mole ratio is about 1:5;
- (c) the liposomes have a mean diameter of less than 250 nm;
- and
- (d) wherein the liposomes comprise DSPC, DSPG and cholesterol in a mole ratio of about 7:2:1.
A composition for parental administration to a subject which composition comprises liposomes having associated therewith daunorubicin and cytarabine, and wherein
- (a) the daunorubicin and cytarabine are co-encapsulated;
- (b) the daunorubicin:cytarabine mole ratio is about 1:5;
- (c) the composition comprises no therapeutic agents in addition to the daunorubicin and cytarabine;
- and
- (d) wherein the liposomes comprise DSPC, DSPG and cholesterol in a mole ratio of about 7:2:1.
Dependencies are inferred from the claim text.